Iluvien

Fluocinolone Acetonide, the active ingredient in Iluvien, is a corticosteroid presented as a 0.19 mg intravitreal sustained‑release implant for intravitreal use. It treats chronic diabetic macular edema and non‑infectious posterior uveitis in patients whose disease has not responded adequately to other therapies.

GNH USA supplies Iluvien as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iluvien is used in ophthalmology to manage chronic retinal conditions characterized by inflammation and fluid accumulation.

- Chronic diabetic macular edema: reduces retinal swelling and improves visual acuity in patients unresponsive to other treatments. - Non‑infectious posterior uveitis: decreases intra‑ocular inflammation and helps preserve vision in chronic posterior segment inflammation.

Iluvien may cause ocular and systemic adverse reactions that vary in frequency and severity.

Common Side Effects: - Increased intraocular pressure: may require topical or systemic pressure‑lowering therapy. - Cataract progression: accelerated lens opacity especially in phakic eyes. - Ocular pain or discomfort after injection. - Vitreous floaters or transient visual disturbances. - Conjunctival hemorrhage at the injection site.

Serious or Rare Side Effects: - Endophthalmitis: intra‑ocular infection requiring urgent treatment. - Retinal detachment or tear. - Implant migration into the anterior chamber. - Persistent or severe intra‑ocular inflammation. - Optic nerve damage or vision loss.

Prior to Iluvien implantation, clinicians should assess ocular health and monitor for potential complications.

- Intraocular pressure monitoring: check baseline and follow‑up pressures regularly. - Cataract evaluation: assess lens status before and during treatment. - Avoid in active ocular infection: postpone implantation until infection resolves. - Caution in patients with uncontrolled glaucoma: risk of pressure spikes may outweigh benefits. - Hypersensitivity screening: do not use if known allergy to fluocinolone acetonide or implant components. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Iluvien may interact with other ocular or systemic therapies; awareness helps mitigate risks.

Major Interactions (Avoid): - Systemic corticosteroids: may increase systemic glucocorticoid exposure and related adverse effects. - Potent immunosuppressants (e.g., biologics): heightened risk of intra‑ocular infection. - Recent intra‑ocular surgery (within 6 weeks): may impair wound healing.

Moderate Interactions (Monitor Closely): - Topical ocular steroids: cumulative intra‑ocular pressure elevation. - Anti‑glaucoma medications: may require dose adjustment if pressure rises. - Anti‑VEGF agents: potential additive effect on retinal fluid control. - Non‑steroidal anti‑inflammatory eye drops: monitor for delayed healing.